1. Home
  2. CURX vs CWD Comparison

CURX vs CWD Comparison

Compare CURX & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CURX

Curanex Pharmaceuticals Inc

HOLD

Current Price

$0.22

Market Cap

9.4M

Sector

Health Care

ML Signal

HOLD

Logo CaliberCos Inc.

CWD

CaliberCos Inc.

HOLD

Current Price

$0.57

Market Cap

10.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CURX
CWD
Founded
2018
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.4M
10.0M
IPO Year
2024
2022

Fundamental Metrics

Financial Performance
Metric
CURX
CWD
Price
$0.22
$0.57
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
90.2K
243.2K
Earning Date
09-09-2025
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$20,097,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$19.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.43
52 Week High
$9.18
$46.21

Technical Indicators

Market Signals
Indicator
CURX
CWD
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
CURX
CWD

About CURX Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.

About CWD CaliberCos Inc.

CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.

Share on Social Networks: